Srivicha KrudsoodNoppadon TangpukdeePolrat WilairatanaNantaporn PothipakChatnapa DuangdeeDavid A. WarrellSornchai LooareesuwanNuffield Department of Clinical MedicineMahidol University2018-09-242018-09-242010-07-01American Journal of Tropical Medicine and Hygiene. Vol.83, No.1 (2010), 51-55000296372-s2.0-77954579197https://repository.li.mahidol.ac.th/handle/20.500.14594/29214Because some febrile patients are unable to swallow or retain oral antipyretic drugs, we carried out a double-blind, placebo-controlled trial in which intravenous ibuprofen (IV-ibuprofen) was given to adults hospitalized with fever associated with acute uncomplicated falciparum malaria treated with oral artesunate plus mefloquine. Thirty patients received IV-ibuprofen 400 mg and 30 received placebo every 6 hours for 72 hours. Reduction in the area above 37.0°C versus time curve was significantly greater for IV-ibuprofen than for placebo during the first 72 hours after first administration. No patients developed severe malaria; parasite clearance was delayed in the patients whose fevers were controlled by IV-ibuprofen (median 37.3 hours versus 23.7 hours in the placebo group [P = 0.0024]). This difference did not appear to be clinically important Adverse events, none considered severe, occurred equally in both groups. IV-ibuprofen was effective and well tolerated in reducing fever in febrile inpatients with malaria. Copyright © 2010 by The American Society of Tropical Medicine and Hygiene.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.4269/ajtmh.2010.09-0621